Clinical trials / NCT03038022
NCT03038022Phase 2Completed

Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Study sponsor: Madrigal Pharmaceuticals, Inc. · MDGL

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2018-01-15Actual
Enrollment · participants116Actual
Source updated2026-06-04Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Mean Percentage Change in LDL-C From Baseline To Week 12

+ After

Measure: Mean Percent Change in LDL-C From Baseline To Week 12

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C)

+ After

Measure: Mean Percentage Change in LDL-C From Baseline To Week 12

Primary completion date changed

− Before

18 Dec 2017

+ After

15 Jan 2018

Check registry source